Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”

The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Joyner, Michael J., Paneth, Nigel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765513/
https://www.ncbi.nlm.nih.gov/pubmed/36314790
http://dx.doi.org/10.1128/mbio.02653-22
_version_ 1784853505574436864
author Joyner, Michael J.
Paneth, Nigel
author_facet Joyner, Michael J.
Paneth, Nigel
author_sort Joyner, Michael J.
collection PubMed
description The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined.
format Online
Article
Text
id pubmed-9765513
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-97655132022-12-21 Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study” Joyner, Michael J. Paneth, Nigel mBio Commentary The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined. American Society for Microbiology 2022-10-31 /pmc/articles/PMC9765513/ /pubmed/36314790 http://dx.doi.org/10.1128/mbio.02653-22 Text en Copyright © 2022 Joyner and Paneth. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Commentary
Joyner, Michael J.
Paneth, Nigel
Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
title Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
title_full Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
title_fullStr Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
title_full_unstemmed Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
title_short Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
title_sort commentary on “outcomes of convalescent plasma with defined high versus lower neutralizing antibody titers against sars-cov-2 among hospitalized patients: coronavirus inactivating plasma (covip) study”
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765513/
https://www.ncbi.nlm.nih.gov/pubmed/36314790
http://dx.doi.org/10.1128/mbio.02653-22
work_keys_str_mv AT joynermichaelj commentaryonoutcomesofconvalescentplasmawithdefinedhighversuslowerneutralizingantibodytitersagainstsarscov2amonghospitalizedpatientscoronavirusinactivatingplasmacovipstudy
AT panethnigel commentaryonoutcomesofconvalescentplasmawithdefinedhighversuslowerneutralizingantibodytitersagainstsarscov2amonghospitalizedpatientscoronavirusinactivatingplasmacovipstudy

Ejemplares similares